A comparison of model-free phase I dose escalation designs for dual-agent combination therapies
It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct phase I trials in this setting are available, where the objective is to select the maximum tolerated dose combination. Recently, a number of model-free (also called model-assisted) designs have provoked interest, providing several practical advantages over the more conventional approaches of rule-based or model-based designs. In this paper, we demonstrate a novel calibration procedure for model-free designs to determine their most desirable parameters. Under the calibration procedure, we compare the behaviour of model-free designs to model-based designs in a comprehensive simulation study, covering a number of clinically plausible scenarios. It is found that model-free designs are competitive with the model-based designs in terms of the proportion of correct selections of the maximum tolerated dose combination. However, there are a number of scenarios in which model-free designs offer a safer alternative. This is also illustrated in the application of the designs to a case study using data from a phase I oncology trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Statistical methods in medical research - 33(2024), 2 vom: 21. Feb., Seite 203-226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barnett, Helen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combination therapies |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/09622802231220497 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367543214 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367543214 | ||
| 003 | DE-627 | ||
| 005 | 20240323000617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/09622802231220497 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM367543214 | ||
| 035 | |a (NLM)38263903 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barnett, Helen |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparison of model-free phase I dose escalation designs for dual-agent combination therapies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct phase I trials in this setting are available, where the objective is to select the maximum tolerated dose combination. Recently, a number of model-free (also called model-assisted) designs have provoked interest, providing several practical advantages over the more conventional approaches of rule-based or model-based designs. In this paper, we demonstrate a novel calibration procedure for model-free designs to determine their most desirable parameters. Under the calibration procedure, we compare the behaviour of model-free designs to model-based designs in a comprehensive simulation study, covering a number of clinically plausible scenarios. It is found that model-free designs are competitive with the model-based designs in terms of the proportion of correct selections of the maximum tolerated dose combination. However, there are a number of scenarios in which model-free designs offer a safer alternative. This is also illustrated in the application of the designs to a case study using data from a phase I oncology trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dose-finding | |
| 650 | 4 | |a combination therapies | |
| 650 | 4 | |a model-free designs | |
| 650 | 4 | |a phase I trials | |
| 700 | 1 | |a George, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Skanji, Donia |e verfasserin |4 aut | |
| 700 | 1 | |a Saint-Hilary, Gaelle |e verfasserin |4 aut | |
| 700 | 1 | |a Jaki, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mozgunov, Pavel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Statistical methods in medical research |d 1997 |g 33(2024), 2 vom: 21. Feb., Seite 203-226 |w (DE-627)NLM013229338 |x 1477-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2024 |g number:2 |g day:21 |g month:02 |g pages:203-226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/09622802231220497 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2024 |e 2 |b 21 |c 02 |h 203-226 | ||